• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Impact of aging and HIV infection on serologic response to seasonal influenza vaccination

tetano

Editor, Senior Moderator
AIDS. 2018 Feb 8. doi: 10.1097/QAD.0000000000001774. [Epub ahead of print]
[h=1]Impact of aging and HIV infection on serologic response to seasonal influenza vaccination.[/h] Pallikkuth S[SUP]1[/SUP], De Armas LR[SUP]1[/SUP], Pahwa R[SUP]1[/SUP], Rinaldi S[SUP]1[/SUP], George VK[SUP]1[/SUP], Sanchez CM[SUP]1[/SUP], Pan L[SUP]1[/SUP], Dickinson G[SUP]2,[/SUP][SUP]3[/SUP], Rodriguez A[SUP]2[/SUP], Fischl M[SUP]4[/SUP], Alcaide M[SUP]2[/SUP], Pahwa S[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]OBJECTIVE:[/h] To determine influence of age and HIV infection on influenza vaccine responses.
[h=4]DESIGN:[/h] Evaluate serologic response to seasonal trivalent influenza vaccine (TIV) as the immunologic outcome in HIV-infected (HIV) and age-matched HIV negative (HIV) adults.
[h=4]METHODS:[/h] During 2013-2016, 151 virologically controlled HIV individuals on antiretroviral therapy and 164 HIV volunteers grouped by age as young (<40 years), middle aged (40-59 years) and old (≥60 years) were administered TIV and investigated for serum antibody response to vaccine antigens.
[h=4]RESULTS:[/h] At prevaccination (T0) titers were in seroprotective range in more than 90% of participants. Antibody titers increased in all participants postvaccination but frequency of classified vaccine responders to individual or all three vaccine antigens at 3-4 weeks was higher in HIV than HIV adults with the greatest differences manifesting in the young age group. Of the three vaccine strains in TIV, antibody responses at T2 were weakest against H3N2 with those to H1N1 and B antigens dominating. Among the age groups, the titers for H1N1 and B were lowest in old age, with evidence of an age-associated interaction in HIV persons with antibody to B antigen.
[h=4]CONCLUSION:[/h] Greater frequencies of vaccine nonresponders are seen in HIV young compared with HIV adults and the observed age-associated interaction for B antigen in HIV persons are supportive of the concept of premature immune senescence in controlled HIV infection. High-potency influenza vaccination recommended for healthy aging could be considered for HIV adults of all ages.


PMID: 29424779 DOI: 10.1097/QAD.0000000000001774
 
Back
Top Bottom